A possible reason electric field therapy stops working for some people
Original title: CPT1A-mediated IDO1 succinylation shapes EGFRvIII-driven resistance to tumor electric field therapy in glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
Most of this work was done in lab cells and mice.
The short version
Scientists found a reason why a brain tumor device may fail in some patients.
What was studied. Electric field therapy is a device used against a brain tumor called glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary. Researchers looked back at patients who had this therapy. They also tested tumor cells, lab grown tumors, and mice.
What they found. Tumors with a gene change called EGFRvIII came back sooner after the therapy. In the lab, these tumors turned on a chain of steps that helped them survive the electric fields. Blocking that chain made the therapy work again in cells and in mice. A drug called osimertinib blocked part of that chain.
What this means, and what it doesn't
What it could mean: This may help explain why the device helps some people more than others. It points to a drug that might make the device work better. Doctors would need to test that idea in a real trial first.
What it doesn't mean: This does not mean a new treatment is ready for you. Most of this work was done in lab cells and in mice. Only a few patient cases were looked at, and only in an early way. It is not proof that this drug plus the device works. It is not a cure.
Source: PubMed, September 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.